{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T09:38:06Z","timestamp":1793957886946,"version":"4.8.0"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","funder":[{"name":"Mid-America Transplant","award":["Clinical Innovation Award"],"award-info":[{"award-number":["Clinical Innovation Award"]}]},{"name":"Mid-America Transplant\/Jane A. Beckman Endowed Chair in Transplantation"},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01DK120518"],"award-info":[{"award-number":["R01DK120518"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kidney360"],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Transplant practices related to use of organs from hepatitis C virus\u2013infected donors (DHCV+) is evolving rapidly.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We surveyed US kidney transplant programs by email and professional society LISTSERV postings between July 2019 and January 2020 to assess attitudes, management strategies, and barriers related to use of viremic (nucleic acid testing positive [NAT+]) donor organs in recipients who are not infected with HCV.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Staff at 112 unique programs responded, representing 54% of US adult kidney transplant programs and 69% of adult deceased donor kidney transplant volume in 2019. Most survey respondents were transplant nephrologists (46%) or surgeons (43%). Among the responding programs, 67% currently transplant DHCV antibody+\/NAT\u2212 organs under a clinical protocol or as standard of care. By comparison, only 58% offer DHCV NAT+ kidney transplant to recipients who are HCV\u2212, including 35% under clinical protocols, 14% as standard of care, and 9% under research protocols. After transplant of DHCV NAT+ organs to recipients who are uninfected, 53% start direct-acting antiviral agent (DAA) therapy after discharge and documented viremia. Viral monitoring protocols after DHCV NAT+ to HCV uninfected recipient kidney transplantation varied substantially. 56% of programs performing these transplants report having an institutional plan to provide DAA treatment if declined by the recipient\u2019s insurance. Respondents felt a mean decrease in waiting time of \u226518 months (range, 0\u201360) justifies the practice. Program concerns related to use of DHCV NAT+ kidneys include insurance coverage concerns (72%), cost (60%), and perceived risk of transmitting resistant infection (44%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Addressing knowledge about safety and logistic\/financial barriers related to use of DHCV NAT+ kidney transplantation for recipients who are not infected with HCV may help reduce discards and expand the organ supply.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Podcast<\/jats:title>\n                    <jats:p>This article contains a podcast at https:\/\/www.asn-online.org\/media\/podcast\/K360\/2020_11_25_KID0004592020.mp3<\/jats:p>\n                  <\/jats:sec>","DOI":"10.34067\/kid.0004592020","type":"journal-article","created":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T16:50:17Z","timestamp":1599151817000},"page":"1291-1299","source":"Crossref","is-referenced-by-count":33,"title":["Survey of Clinician Opinions on Kidney Transplantation from Hepatitis C Virus Positive Donors: Identifying and Overcoming Barriers"],"prefix":"10.34067","volume":"1","author":[{"given":"Krista L.","family":"Lentine","sequence":"first","affiliation":[{"name":"Center for Abdominal Transplantation, Saint Louis University School of Medicine, St. Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Peipert","sequence":"additional","affiliation":[{"name":"Department of Medical Social Sciences, Feinberg School of Medicine, Northwestern University, Chicago, Illinois"},{"name":"Transplant Outcomes Research Core, Northwestern University, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek","family":"Alhamad","sequence":"additional","affiliation":[{"name":"Washington University Transplant Center, Washington University School of Medicine, Saint Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasar","family":"Caliskan","sequence":"additional","affiliation":[{"name":"Center for Abdominal Transplantation, Saint Louis University School of Medicine, St. Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice P.","family":"Concepcion","sequence":"additional","affiliation":[{"name":"Vanderbilt Transplant Center, Vanderbilt School of Medicine, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Forbes","sequence":"additional","affiliation":[{"name":"Vanderbilt Transplant Center, Vanderbilt School of Medicine, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Schnitzler","sequence":"additional","affiliation":[{"name":"Center for Abdominal Transplantation, Saint Louis University School of Medicine, St. Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-Hsin","family":"Chang","sequence":"additional","affiliation":[{"name":"Washington University Transplant Center, Washington University School of Medicine, Saint Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Cooper","sequence":"additional","affiliation":[{"name":"Medstar Georgetown Transplant Institute, Georgetown University, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy D.","family":"Bloom","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roslyn B.","family":"Mannon","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, University of Nebraska, Omaha, Nebraska"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Axelrod","sequence":"additional","affiliation":[{"name":"Transplant Institute, Department of Surgery, University of Iowa, Iowa City, Iowa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,11,25]]},"reference":[{"issue":"Suppl 1","key":"B1-20230821","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/ajt.15672","article-title":"OPTN\/SRTR 2018 annual data report: Kidney","volume":"20","author":"Hart","year":"2020","journal-title":"Am J Transplant"},{"key":"B2-20230821","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1002\/hep.29572","article-title":"The rise of the opioid epidemic and hepatitis C-positive organs: A new era in liver transplantation","volume":"67","author":"Gonzalez","year":"2018","journal-title":"Hepatology"},{"key":"B3-20230821","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1111\/j.1600-6143.2010.03091.x","article-title":"Underutilization of hepatitis C-positive kidneys for hepatitis C-positive recipients","volume":"10","author":"Kucirka","year":"2010","journal-title":"Am J Transplant"},{"key":"B4-20230821","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1056\/NEJMp1505074","article-title":"Transplanting hepatitis C-positive kidneys","volume":"373","author":"Reese","year":"2015","journal-title":"N Engl J Med"},{"key":"B5-20230821","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1111\/ajt.15355","article-title":"Center-level trends in utilization of HCV-exposed donors for HCV-uninfected kidney and liver transplant recipients in the United States","volume":"19","author":"Bowring","year":"2019","journal-title":"Am J Transplant"},{"key":"B6-20230821","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1111\/ajt.14381","article-title":"The American society of transplantation consensus conference on the use of hepatitis C viremic donors in solid organ transplantation","volume":"17","author":"Levitsky","year":"2017","journal-title":"Am J Transplant"},{"key":"B7-20230821","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1111\/ajt.15031","article-title":"Transplantation of hepatitis C virus (HCV) antibody positive, nucleic acid test negative donor kidneys to HCV negative patients frequently results in seroconversion but not HCV viremia","volume":"18","author":"de Vera","year":"2018","journal-title":"Am J Transplant"},{"key":"B8-20230821","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMc1705221","article-title":"Trial of transplantation of HCV-infected kidneys into uninfected recipients","volume":"376","author":"Goldberg","year":"2017","journal-title":"N Engl J Med"},{"key":"B9-20230821","doi-asserted-by":"crossref","first-page":"533","DOI":"10.7326\/M17-2871","article-title":"Direct-acting antiviral prophylaxis in kidney transplantation from hepatitis C virus-infected donors to noninfected recipients: An open-label nonrandomized trial","volume":"168","author":"Durand","year":"2018","journal-title":"Ann Intern Med"},{"key":"B10-20230821","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1111\/ajt.14895","article-title":"The impact of direct-acting antiviral agents on liver and kidney transplant costs and outcomes","volume":"18","author":"Axelrod","year":"2018","journal-title":"Am J Transplant"},{"key":"B11-20230821","doi-asserted-by":"crossref","first-page":"e014495","DOI":"10.1161\/JAHA.119.014495","article-title":"Outcomes of adult heart transplantation using hepatitis C-positive donors","volume":"9","author":"Kilic","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"B12-20230821","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/ajt.15664","article-title":"Ultra-short duration direct acting antiviral prophylaxis to prevent virus transmission from hepatitis C viremic donors to hepatitis C negative kidney transplant recipients","volume":"20","author":"Gupta","year":"2020","journal-title":"Am J Transplant"},{"key":"B13-20230821","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S2213-2600(19)30268-1","article-title":"Prevention of viral transmission during lung transplantation with hepatitis C-viraemic donors: An open-label, single-centre, pilot trial","volume":"8","author":"Cypel","year":"2020","journal-title":"Lancet Respir Med"},{"key":"B14-20230821","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1111\/ajt.15768","article-title":"Immediate administration of antiviral therapy after transplantation of hepatitis C-infected livers into uninfected recipients: Implications for therapeutic planning","volume":"20","author":"Bethea","year":"2020","journal-title":"Am J Transplant"},{"key":"B15-20230821","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1111\/ajt.15530","article-title":"Transplantation of kidneys from hepatitis C-infected donors to hepatitis C-negative recipients: Single center experience","volume":"19","author":"Molnar","year":"2019","journal-title":"Am J Transplant"},{"key":"B16-20230821","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1056\/NEJMoa1812406","article-title":"Heart and lung transplants from HCV-infected donors to uninfected recipients","volume":"380","author":"Woolley","year":"2019","journal-title":"N Engl J Med"},{"key":"B17-20230821","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.ekir.2020.01.001","article-title":"Preemptive treatment with elbasvir and grazoprevir for hepatitis C-viremic donor to uninfected recipient kidney transplantation","volume":"5","author":"Sise","year":"2020","journal-title":"Kidney Int Rep"},{"key":"B18-20230821","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.ekir.2020.02.001","article-title":"Kidney transplantation from a hepatitis C virus-infected donor into an uninfected recipient: Ready for prime time?","volume":"5","author":"Pagan","year":"2020","journal-title":"Kidney Int Rep"},{"key":"B19-20230821","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1111\/j.1600-6143.2007.01932.x","article-title":"The medical evaluation of living kidney donors: A survey of US transplant centers","volume":"7","author":"Mandelbrot","year":"2007","journal-title":"Am J Transplant"},{"key":"B20-20230821","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1097\/TP.0b013e3181b6dfb9","article-title":"Practices and barriers in long-term living kidney donor follow-up: A survey of U.S. Transplant centers","volume":"88","author":"Mandelbrot","year":"2009","journal-title":"Transplantation"},{"key":"B21-20230821","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13088","article-title":"Practices in the evaluation of potential kidney transplant recipients who are elderly: A survey of U.S. transplant centers","volume":"31","author":"Mandelbrot","year":"2017","journal-title":"Clin Transplant"},{"key":"B22-20230821","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1111\/ajt.14444","article-title":"Social media and organ donation: Ethically navigating the next frontier","volume":"17","author":"Henderson","year":"2017","journal-title":"Am J Transplant"},{"key":"B23-20230821","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1111\/ajt.14386","article-title":"Utilization of organs from donors according to hepatitis C antibody and nucleic acid testing status: Time for change","volume":"17","author":"Kling","year":"2017","journal-title":"Am J Transplant"},{"key":"B24-20230821","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1111\/ajt.12400","article-title":"Successful treatment of chronic HCV infection should not preclude kidney donation to an HCV negative recipient","volume":"13","author":"Cruzado","year":"2013","journal-title":"Am J Transplant"},{"key":"B25-20230821","doi-asserted-by":"crossref","first-page":"273","DOI":"10.7326\/M18-0749","article-title":"Twelve-month outcomes after transplant of hepatitis C-infected kidneys into uninfected recipients: A single-group trial","volume":"169","author":"Reese","year":"2018","journal-title":"Ann Intern Med"},{"key":"B26-20230821","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1053\/j.ajkd.2019.11.005","article-title":"Cost-effectiveness of using kidneys from HCV-viremic donors for transplantation into HCV-uninfected recipients","volume":"75","author":"Eckman","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"B27-20230821","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/hep.31011","article-title":"Hepatitis C virus NAT-positive solid organ allografts transplanted into HCVnegative recipients: A real-world experience","volume":"72","author":"Kapila","year":"2020","journal-title":"Hepatology"},{"key":"B28-20230821","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/jvh.13042","article-title":"Transplantation of kidneys from HCV viremic donors to HCV viremic recipients followed by early direct acting antiviral therapy without ribavirin","volume":"26","author":"Kapila","year":"2019","journal-title":"J Viral Hepat"},{"key":"B29-20230821","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1681\/ASN.2019050462","article-title":"National trends in utilization and 1-year outcomes with transplantation of HCV-viremic kidneys","volume":"30","author":"Potluri","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"B30-20230821","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/TP.0000000000001953","article-title":"Long-term patient and graft survival of kidney transplant recipients with hepatitis C virus infection in the United States","volume":"102","author":"Heo","year":"2018","journal-title":"Transplantation"},{"key":"B31-20230821","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1111\/ajt.14929","article-title":"Cost-effectiveness of using kidneys from hepatitis C nucleic acid test-positive donors for transplantation in hepatitis C-negative recipients","volume":"18","author":"Kadatz","year":"2018","journal-title":"Am J Transplant"},{"key":"B32-20230821","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/ctr.12582","article-title":"Changing the paradigm of organ utilization from PHS increased-risk donors: An opportunity whose time has come?","volume":"29","author":"Sibulesky","year":"2015","journal-title":"Clin Transplant"},{"key":"B33-20230821","doi-asserted-by":"crossref","first-page":"917","DOI":"10.2215\/CJN.08251109","article-title":"Determinants of the decision to accept a kidney from a donor at increased risk for blood-borne viral infection","volume":"5","author":"Reese","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"B34-20230821","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1399-0012.2011.01469.x","article-title":"Patient attitudes toward CDC high infectious risk donor kidney transplantation: Inferences from focus groups","volume":"26","author":"Ros","year":"2012","journal-title":"Clin Transplant"},{"key":"B35-20230821","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/lt.22437","article-title":"Patient decision making about organ quality in liver transplantation","volume":"17","author":"Volk","year":"2011","journal-title":"Liver Transpl"},{"key":"B36-20230821","doi-asserted-by":"crossref","first-page":"e0135645","DOI":"10.1371\/journal.pone.0135645","article-title":"Drug authorization for sofosbuvir\/ledipasvir (harvoni) for chronic HCV infection in a real-world cohort: A new barrier in the HCV care cascade","volume":"10","author":"Do","year":"2015","journal-title":"PLoS One"},{"key":"B37-20230821","first-page":"152","article-title":"Direct acting antiviral therapy after liver transplantation","volume":"32","author":"Kwo","year":"2016","journal-title":"Curr Opin Gastroenterol"},{"key":"B38-20230821","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.kint.2017.10.024","article-title":"Direct-acting antiviral therapy for hepatitis C virus infection in the kidney transplant recipient","volume":"93","author":"Chute","year":"2018","journal-title":"Kidney Int"},{"key":"B39-20230821","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1002\/hep.30046","article-title":"Glecaprevir\/pibrentasvir treatment in liver or kidney transplant patients with hepatitis C virus infection","volume":"68","author":"Reau","year":"2018","journal-title":"Hepatology"},{"key":"B41-20230821","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1111\/ajt.15054","article-title":"Cost-effectiveness of hepatitis C-positive donor kidney transplantation for hepatitis C-negative recipients with concomitant direct-acting antiviral therapy","volume":"18","author":"Gupta","year":"2018","journal-title":"Am J Transplant"}],"container-title":["Kidney360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0004592020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T19:57:15Z","timestamp":1786478235000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0004592020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":40,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.34067\/kid.0004592020","relation":{},"ISSN":["2641-7650"],"issn-type":[{"value":"2641-7650","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11]]}}}